Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

Drugs that target the EGFR protein and block its activity include: afatinib (Gilotrif) dacomitinib (Vizimpro) erlotinib (Tarceva) gefitinib (Iressa) osimertinib (Tagrisso) The most effective ...

But this early poster child for pharmacogenetics has yet to live up to its hype. A tyrosine kinase inhibitor, Iressa blocks the epidermal growth factor receptor (EGFR), a protein overexpressed in many ...

The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...

One of the first EGFR inhibitors in the clinic is gefitinib (Iressa®), a small-molecule tyrosine-kinase inhibitor (TKI). Following four phase I studies, two large phase II trials (IDEAL I and II ...

Roche's Tarceva and AstraZeneca's own Iressa are the current standard of ... These patients are particularly sensitive to treatment with existing EGFR-TKIs, which block the cell signalling ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

"Despite the extended survival observed in patients with EGFR variations treated with osimertinib compared with gefitinib [Iressa] or erlotinib [Tarceva], long-term outcomes may be compromised by ...

While there are plenty of EGFR-targeting drugs on the market for ... like AstraZeneca's market-leading Tagrisso (osimertinib), AZ’s older Iressa (gefitinib) and Roche’s Tarceva (erlotinib).